Understanding genetic changes in pediatric solid tumors
Implementation of a Comprehensive Multi-level Molecular Strategy for the Identification of Genetic Alterations in Pediatric Solid Tumors Aimed at Achieving a Personalized Approach to the Patient
This study is trying to find out how genetic changes in children's solid tumors can help doctors create better, personalized treatments for kids with conditions like neuroblastoma and rhabdomyosarcoma.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | N/A to 18 Years |
| Sex | All |
| Sponsor | National Council of Scientific and Technical Research, Argentina Government |
| Locations | 1 site (Ciudad Autónoma de Buenos Aires) |
| Trial ID | NCT04773808 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on the molecular characterization of genetic alterations in pediatric solid tumors, including neuroblastoma, rhabdomyosarcoma, and CNS tumors. By collecting tumor samples at various stages, the study aims to identify specific molecular markers that can guide tailored therapies for affected children. The research is conducted at Hospital de Niños R Gutierrez and aims to improve diagnostic accuracy and treatment options for pediatric patients with solid tumors. The findings could lead to more personalized treatment approaches based on the unique biology of each tumor.
Who should consider this trial
Good fit: Ideal candidates include children under 18 with a suspected or confirmed diagnosis of specific pediatric solid tumors.
Not a fit: Patients without access to tumor tissue samples or who cannot provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enable more effective and personalized treatment strategies for children with solid tumors.
How similar studies have performed: Other studies have shown promise in using molecular characterization for tailored therapies in pediatric tumors, indicating a potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Must have a suspected or known diagnosis of neuroblastoma, rhabdomyosarcoma, Ewing sarcoma family tumors, soft tissue sarcomas and CNS tumors (gliomas and embryonal) based on the initial diagnostic workup and evidence of gross disease amenable to excision. Specimens may be collected at some or all of the following time points: initial biopsy, tumor resection and at time of possible relapse. 2. The patient or his/her legal guardian, as appropriate, must provide written informed consent within 30 days of the removal of the first collection of tissue sample for this protocol. 3. The patient is being seen at Hospital de Niños R Gutierrez or at a collaborating institution. 4. Patients must be less than or equal to 18 years old at the time of enrollment. Exclusion Criteria: 1. No access to the tumor tissue sample. 2. written informed consent is not obtained.
Where this trial is running
Ciudad Autónoma de Buenos Aires
- Maria Victoria Preciado — Ciudad Autónoma de Buenos Aires, Argentina (Recruiting)
Study contacts
- Study coordinator: Maria Victoria Preciado, PhD
- Email: mvpreciado67@gmail.com
- Phone: +5491144916970
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.